Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

本文源自：金融界AI电报 景瑞控股(01862.HK)公布，该集团于2025年7月的合约签约销售额(连合营企业及联营企业的销售额)约 为人民币0.99亿元，同比减少65.51%;合同销售面积约为6,446平方米，合同销售均价约人民币15,358元 ╱平方米。 ...

景瑞控股(01862)公布，该集团于2025年7月的合约签约销售额(连合营企业及联营企业的销售额)约为人 民币0.99亿元，同比减少65.51%;合同销售面积约为6,446平方米，合同销售均价约人民币15,358元╱平 方米。 截至2025年7月31日止七个月，该集团累计合约签约销售额(连合营企业及联营企业的销售额)约为人民 币5.71亿元，同比减少52.54%;合同销售面积约为39,221平方米，合同销售均价约人民币14,559元╱平方 米。 ...

格隆汇8月6日丨景瑞控股(01862.HK)公布，集团于2025年7月的合约签约销售额(连合营企业及联营企业 的销售额)约为人民币0.99亿元，合同销售面积约为6,446平方米，合同销售均价约人民币15,358元╱平 方米。 截至2025年7月31日止七个月，集团累计合约签约销售额(连合营企业及联营企业的销售额)约为人民币 5.71亿元，合同销售面积约为39,221平方米，合同销售均价约人民币14,559元╱平方米。 ...

景瑞控股(01862)公布，该集团于2025年7月的合约签约销售额(连合营企业及联营企业的销售额)约为人 民币0.99亿元，同比减少65.51%;合同销售面积约为6,446平方米，合同销售均价约人民币15,358元╱平 方米。 截至2025年7月31日止七个月，该集团累计合约签约销售额(连合营企业及联营企业的销售额)约为人民 币5.71亿元，同比减少52.54%;合同销售面积约为39,221平方米，合同销售均价约人民币14,559元╱平方 米。 ...

（股份代號：01862） 2025年7月未經審計的營運數據 景瑞控股有限公司*（「本公司」）董事會（「董事會」）欣然公佈本公司及其附屬公司（「本集團」）2025年7月 未經審計的營運數據。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 JINGRUI HOLDINGS LIMITED 景瑞控股有限公司* （於開曼群島註冊成立的有限公司） 本集團於2025年7月的合約簽約銷售額（連合營企業及聯營企業的銷售額）約為人民幣0.99億元，合同 銷售面積約為6,446平方米，合同銷售均價約人民幣15,358元╱平方米。 * 僅供識別 截至2025年7月31日止七個月，本集團累計合約簽約銷售額（連合營企業及聯營企業的銷售額）約為人 民幣5.71億元，合同銷售面積約為39,221平方米，合同銷售均價約人民幣14,559元╱平方米。 上述營運數據未經審計，乃根據本集團初步內部資料編製，鑒於整理該等銷售數據過程中可能存在 各種不確定因素，該等營運數據與本公司按年度或 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 景瑞控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01862 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.01 | USD | | 100,000,000 | | 增加 / 減少 (-) | | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.01 | USD ...

Group 1: Real Estate Industry Mergers and Acquisitions - In the first half of the year, the real estate industry completed 81 merger and acquisition transactions, an increase of 2 compared to the same period in 2024 [1] - The total transaction scale for 60 disclosed transactions was approximately 29.1 billion yuan, representing a year-on-year decline of 58%, indicating a significant contraction in overall M&A activity [1] - Major real estate companies are accelerating the divestiture of non-core assets, while asset management companies (AMCs) and local special bonds are entering the market to provide new solutions for distress and inventory reduction [1] Group 2: Land Recovery in Chongqing - Chongqing plans to recover 2,161 acres of idle land through the issuance of special bonds, with an estimated total recovery price of 3.39 billion yuan [2] - A total of 25 parcels of idle land are expected to be recovered, contributing to a cumulative total of 419 parcels and approximately 29,500 acres across 9 regions, with a total recovery amount of about 48.2 billion yuan [2] - This initiative aims to optimize land resource allocation and reduce ineffective land accumulation, signaling local governments' proactive approach to resource activation and market stabilization [2] Group 3: Gindal Group Organizational Restructuring - Gindal Group announced a new organizational structure, establishing four major regional companies and ten regional companies, shifting from a three-tier to a 2.5-tier management model [3] - This restructuring is expected to enhance management efficiency and focus resources on core markets and businesses, thereby strengthening competitiveness in key regions [3] - The move reflects Gindal's proactive response to market changes, which may help stabilize investor confidence in the company and the industry [3] Group 4: Jingrui Holdings Liquidation Hearing Postponement - Jingrui Holdings' liquidation hearing has been postponed to October 16, 2025, as per the Hong Kong High Court's order [4] - The company has committed to notifying shareholders and investors of any significant developments regarding the petition in accordance with listing rules [4] - This postponement may represent a final opportunity for the company to reach a restructuring agreement, potentially serving as a template for similar companies facing distress [4] Group 5: Dayuecheng Share Unlocking - Dayuecheng announced the unlocking of 283 million shares, accounting for 6.61% of the company's total share capital, with the unlocking date set for August 4, 2025 [5] - The unlocking is based on the approval from the China Securities Regulatory Commission, involving a total fundraising amount of 2.426 billion yuan [5] - This action may increase the tradable shares of Dayuecheng in the market, potentially affecting market liquidity and investor sentiment [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 JINGRUI HOLDINGS LIMITED 景瑞控股有限公司* 押後清盤呈請聆訊 本公告乃由景瑞控股有限公司*（「本公司」）根據香港聯合交易所有限公司證券上市規則（「上市規則」） 第13.09(2)(a)及13.25(1)(b)條以及香港法例第571章證券及期貨條例第XIVA部而作出。 茲提述本公司日期為2024年10月15日、2024年12月18日、2025年1月22日、2025年2月19日、2025年 4月22日及2025年4月28日有關針對本公司的清盤呈請及押後呈請聆訊日期之公告（「該等公告」）。除 非文義另有所指，否則本公告所使用詞彙應具有該等公告所界定的相同涵義。 本公司宣佈，於2025年7月28日，高等法院下令將呈請聆訊進一步押後至2025年10月16日。 本公司將適時根據上市規則的規定另行刊發公告，以知會其股東及投資者有關呈請的任何重大發 展。 本公司股東及潛在投資者於買賣本公司證券 ...

Company Overview - Jingrui Holdings (01862.HK) reported a closing price of HKD 0.018 per share, with a significant increase of 38.46% and a trading volume of 181 million shares, amounting to HKD 3.105 million, with a volatility of 69.23% [1] - The company has experienced a cumulative increase of 30% over the past month, but a year-to-date decline of 51.85%, underperforming the Hang Seng Index by 22.13% [2] - Financial data shows that as of December 31, 2024, Jingrui Holdings achieved total revenue of CNY 5.906 billion, a year-on-year decrease of 19.03%, and a net profit attributable to shareholders of -CNY 3.004 billion, down 74.51% year-on-year, with a gross margin of -4.28% and a debt-to-asset ratio of 97.76% [2] Industry Analysis - Currently, there are no institutional investment ratings for Jingrui Holdings [3] - The average price-to-earnings (P/E) ratio for the real estate industry (TTM) is 10.06 times, with a median of -0.16 times. Jingrui Holdings has a P/E ratio of -0.01 times, ranking 277th in the industry [3] - Other companies in the industry include Baishida Holdings (01168.HK) with a P/E ratio of 0.66 times, Hengda Group Holdings (03616.HK) at 1.71 times, China New City (01321.HK) at 2.27 times, Ruosen Life Services (01922.HK) at 2.82 times, and Xinyuan Services (01895.HK) at 3.03 times [3] Corporate Background - Jingrui Holdings was founded in Shanghai in 1993 and was listed on the Hong Kong Stock Exchange in 2013 (stock code: 1862.HK) [3] - The company operates five major business platforms: Youyue Asset Management, Jingrui Real Estate, Jingrui Real Estate Services, Hefeng Capital, focusing on real estate asset management, with an emphasis on residential development, apartments, and offices in core cities and metropolitan areas [3]